These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 10690517)

  • 41. Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer.
    Wong JY; Somlo G; Odom-Maryon T; Williams LE; Liu A; Yamauchi D; Wu AM; Yazaki P; Wilczynski S; Shively JE; Forman S; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3224s-3231s. PubMed ID: 10541368
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.
    Sharkey RM; Hajjar G; Yeldell D; Brenner A; Burton J; Rubin A; Goldenberg DM
    J Nucl Med; 2005 Apr; 46(4):620-33. PubMed ID: 15809485
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response.
    Jacobs AJ; Fer M; Su FM; Breitz H; Thompson J; Goodgold H; Cain J; Heaps J; Weiden P
    Obstet Gynecol; 1993 Oct; 82(4 Pt 1):586-93. PubMed ID: 8377986
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
    Cremonesi M; Ferrari M; Chinol M; Stabin MG; Grana C; Prisco G; Robertson C; Tosi G; Paganelli G
    Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer.
    Meredith RF; Khazaeli MB; Plott WE; Saleh MN; Liu T; Allen LF; Russell CD; Orr RA; Colcher D; Schlom J
    J Nucl Med; 1992 Jan; 33(1):23-9. PubMed ID: 1730991
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
    Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
    J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
    Alvarez RD; Huh WK; Khazaeli MB; Meredith RF; Partridge EE; Kilgore LC; Grizzle WE; Shen S; Austin JM; Barnes MN; Carey D; Schlom J; LoBuglio AF
    Clin Cancer Res; 2002 Sep; 8(9):2806-11. PubMed ID: 12231520
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas.
    Pagel JM; Hedin N; Subbiah K; Meyer D; Mallet R; Axworthy D; Theodore LJ; Wilbur DS; Matthews DC; Press OW
    Blood; 2003 Mar; 101(6):2340-8. PubMed ID: 12446461
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results.
    Paganelli G; Bartolomei M; Ferrari M; Cremonesi M; Broggi G; Maira G; Sturiale C; Grana C; Prisco G; Gatti M; Caliceti P; Chinol M
    Cancer Biother Radiopharm; 2001 Jun; 16(3):227-35. PubMed ID: 11471487
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of radiolysis on yttrium-90-labeled Lym-1 antibody preparations.
    Salako QA; O'Donnell RT; DeNardo SJ
    J Nucl Med; 1998 Apr; 39(4):667-70. PubMed ID: 9544679
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma.
    Mahé MA; Fumoleau P; Fabbro M; Guastalla JP; Faurous P; Chauvot P; Chetanoud L; Classe JM; Rouanet P; Chatal JF
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3249s-3253s. PubMed ID: 10541371
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin.
    Paganelli G; Grana C; Chinol M; Cremonesi M; De Cicco C; De Braud F; Robertson C; Zurrida S; Casadio C; Zoboli S; Siccardi AG; Veronesi U
    Eur J Nucl Med; 1999 Apr; 26(4):348-57. PubMed ID: 10199940
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.
    Pagel JM; Matthews DC; Kenoyer A; Hamlin DK; Wilbur DS; Fisher DR; Gopal AK; Lin Y; Saganic L; Appelbaum FR; Press OW
    Cancer Res; 2009 Jan; 69(1):185-92. PubMed ID: 19118002
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy.
    Kahn D; Austin JC; Maguire RT; Miller SJ; Gerstbrein J; Williams RD
    Cancer Biother Radiopharm; 1999 Apr; 14(2):99-111. PubMed ID: 10850293
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
    Kosmas C; Snook D; Gooden CS; Courtenay-Luck NS; McCall MJ; Meares CF; Epenetos AA
    Cancer Res; 1992 Feb; 52(4):904-11. PubMed ID: 1737353
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy.
    Kosmas C; Maraveyas A; Gooden CS; Snook D; Epenetos AA
    J Nucl Med; 1995 May; 36(5):746-53. PubMed ID: 7738643
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer.
    Meredith RF; Khazaeli MB; Liu T; Plott G; Wheeler RH; Russell C; Colcher D; Schlom J; Shochat D; LoBuglio AF
    J Nucl Med; 1992 Sep; 33(9):1648-53. PubMed ID: 1517839
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity.
    Axworthy DB; Reno JM; Hylarides MD; Mallett RW; Theodore LJ; Gustavson LM; Su F; Hobson LJ; Beaumier PL; Fritzberg AR
    Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1802-7. PubMed ID: 10677537
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer.
    Meredith RF; Khazaeli MB; Macey DJ; Grizzle WE; Mayo M; Schlom J; Russell CD; LoBuglio AF
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3254s-3258s. PubMed ID: 10541372
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rhenium-186-labeled chimeric antibody NR-LU-13: pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10.
    Weiden PL; Breitz HB; Seiler CA; Bjorn MJ; Ratliff BA; Mallett R; Beaumier PL; Appelbaum JW; Fritzberg AR; Salk D
    J Nucl Med; 1993 Dec; 34(12):2111-9. PubMed ID: 8254397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.